Business
Announcement of Collaboration
Announcement of Collaboration.
About this update from Physiomics Plc
[{"type":"text","content":"\n \n 28 March 2023\n \n \n Physiomics plc\n \n \n (\"Physiomics\" or \"the Company\")\n \n \n \n \n \n \n \n \n Announcement of Collaboration\n \n \n \n \n \n \n Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has signed an agreement with Beyond Blood Diagnostics Ltd (\"Beyond Blood\") (https://beyondblood.co) to analyse data generated during testing of its diagnostic platform using Physiomics' personalised dosing software.\n \n \n Beyond Blood is a seed-stage spin out from Imperial College London, which is developing a patented flow cytometry device to measure blood cell counts (such as neutrophils) in very small blood volumes. Beyond Blood is developing a device that is intended to be small, simple to use and inexpensive, allowing it to be used by patients in a home setting and without the need for taking blood using a syringe. Beyond Blood is aiming for its first products to be commercially available, with approval of the medical device having been sought and obtained, within approximately two years from completion of development.\n \n \n A diagnostic device that enables the collection of neutrophil counts in a home setting could address the challenge (noted in the Company's press release of the 9 January 2023) faced by patients that may be reluctant to travel into hospital for additional blood tests currently required by Physiomics' software in some care settings.\n \n \n Physiomics and Beyond Blood are, in addition, exploring joint grant applications and considering other ways in which Physiomics' software could be used alongside Beyond Blood's devices. It is anticipated that the analysis of data generated by Beyond Blood's diagnostic platform will take place over the course of the balance of this calendar year and further updates will be provided in due course.\n \n \n \n \n \n \n \n \n \n Enquiries:\n \n \n \n \n \n \n \n Physiomics plc\n \n \n \n Dr Jim Millen, CEO\n \n \n +44 (0)1865 784 980\n \n \n \n \n \n \n Hybridan LLP (Broker)\n \n \n \n Claire Louise Noyce\n \n \n +44 (0) 203 764 2341\n \n \n \n \n \n \n Strand Hanson Ltd (NOMAD)\n \n \n \n James Dance & James Bellman\n \n \n +44 (0)20 7409 3...